Cargando…
Loading, please waitCargando…
Loading, please waitCondition Guide
A clear, physician-led overview of how mesenchymal stem cell (MSC) therapy is being studied as a recovery-support adjunct after anterior cruciate ligament (ACL) injury or reconstruction. What the current evidence really shows, when MSC therapy may be considered alongside standard orthopedic care, who is and isn't a candidate — and how our team at Regeneris Therapy in Cancún, México evaluates each case under COFEPRIS oversight.
ACL injury is a structural problem and is treated by orthopedic surgeons — not by stem cells alone. At Regeneris Therapy in Cancún, México, MSC therapy is offered only as an investigational, physician-supervised adjunct to standard care (surgical reconstruction, physical therapy, and supervised return-to-sport). The published clinical evidence in ACL contexts is early-stage and mixed: some randomized studies report improved joint-structural outcomes or graft-recovery signals on MRI, while early patient-reported outcomes often look similar to standard care. Every plan begins with a free medical evaluation, after which patients receive a personalized written quote — Regeneris does not publish prices.
Clinical overview
The anterior cruciate ligament (ACL) is one of the four primary stabilizing ligaments of the knee. A complete tear most often follows a non-contact pivot or deceleration injury and, in active patients, is typically managed surgically — usually with autograft (hamstring or patellar tendon) or allograft reconstruction performed by an orthopedic surgeon, followed by months of structured physical therapy and supervised return-to-sport. Recovery is not a single event; it is a sequence of biological phases (inflammation, graft incorporation, ligamentization, neuromuscular re-learning) that unfolds over six to twelve months or longer. Regenerative therapy enters this picture only as a possible adjunct to that orthopedic care in Cancún, México — never as a substitute for surgery or rehabilitation.
What the research shows
The honest summary is: investigational, with a real but mixed early signal. Several randomized and exploratory human studies have tested MSC-based adjuncts around ACL reconstruction — some report improvements in joint-structural or imaging-based outcomes, others find safety and tolerability without a clear short-term clinical advantage on patient-reported scores. None of these studies justify marketing MSCs as a treatment for ACL tears; they justify continued cautious investigation as an adjunct. The notes below summarize four representative peer-reviewed sources we discuss with patients during evaluation in Cancún, México.
The field's own founder reframed these cells as "medicinal signaling cells," arguing that their benefit comes chiefly from secreted, paracrine factors rather than from engraftment and tissue replacement. This mechanistic framing is the basis of any rational adjunct use around a healing joint — modulating inflammation and the local repair environment, not re-growing the ligament.
A Phase Ib/IIa, controlled, double-blind randomized trial gave 17 patients (aged 18–40) a single intra-articular injection of 75 million allogeneic mesenchymal precursor cells (MPCs) in hyaluronan — versus hyaluronan alone — after ACL reconstruction, with 24 months of follow-up. The authors reported that the single MPC injection was safe and well tolerated, and that it may improve symptoms and joint-structural outcomes, supporting further investigation. The study is small and explicitly investigational.
Patient selection
Candidate selection is a medical decision and depends on imaging, surgical plan, comorbidities, and goals. The lists below are a general orientation, not a self-screening tool. They reflect how our physicians in Cancún, México think about adjunct MSC therapy in the ACL recovery setting.
Regulatory framework
Regeneris Therapy is a COFEPRIS-regulated regenerative medicine clinic in Cancún, Quintana Roo, México. COFEPRIS — Comisión Federal para la Protección contra Riesgos Sanitarios — is Mexico's federal health authority (equivalent in role to the U.S. FDA). Our operating authorizations and supervised physician model are the foundation of every protocol we offer, including any MSC therapy considered as part of an ACL recovery plan.
Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México. Our cell-source chain (Wharton's-jelly umbilical-cord MSCs, bone marrow, or adipose, depending on the protocol) is expanded in sterile, certified laboratory conditions before clinical use.
The Regeneris approach
Our pathway for any ACL-recovery-support inquiry in Cancún, México is the same: a free, physician-led medical evaluation comes first, then — if and only if a Regeneris physician determines MSC therapy could appropriately complement your existing orthopedic plan — a personalized written quote is issued for your records. Regeneris does not publish prices online for any regenerative protocol.
Send us your recent imaging (MRI of the affected knee), your orthopedic surgeon's notes, and your goals. One of our physicians reviews everything personally — never a chatbot, never a sales team.
We tell you whether MSC therapy as a recovery-support adjunct is a reasonable consideration in your specific case — and we tell you when it is not. If the answer is "surgery and physical therapy first," we say so.
When MSC therapy is appropriate, we coordinate timing with your orthopedic surgeon and rehabilitation team. The role of the adjunct is to support, not interrupt, the established recovery trajectory.
Honest expectations
Setting expectations is part of the medicine. Below is what the current evidence does and does not support for MSC therapy in the ACL recovery setting. Anyone — clinic or website — promising you guaranteed regeneration of a torn ligament, faster return-to-sport "on the cells alone," or a single-shot fix is overstating the evidence.
FAQ
The questions patients ask most about MSC therapy as a recovery-support adjunct after ACL injury or reconstruction in Cancún, México.
No. The published clinical evidence does not support using mesenchymal stem cells as a stand-alone treatment for a complete ACL tear, and surgical reconstruction remains the established treatment for active patients. At Regeneris Therapy in Cancún, México, MSC therapy is only considered as an investigational, physician-supervised adjunct alongside standard orthopedic care — not as a replacement for surgery or physical therapy. Any clinic promising you a non-surgical cure for a complete ACL tear is overstating what the evidence shows.
This page is informational and does not constitute medical advice. ACL injury is an orthopedic condition that should be evaluated and treated by a licensed orthopedic surgeon; standard care typically involves surgical reconstruction and structured physical therapy. Mesenchymal stem cell (MSC) therapy described on this page is investigational for ACL contexts and is offered only as a possible adjunct to standard orthopedic care after a physician evaluation. Outcomes vary by patient, injury, surgical plan, and protocol, and no individual outcome is guaranteed. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your recent imaging, your surgeon's notes, and your goals. One of our physicians in Cancún, México will review your case and tell you honestly whether MSC therapy could play a recovery-support role for you — with a personalized written quote only after a free medical evaluation.
Put plainly: a torn ACL is a mechanical problem that orthopedic surgery is designed to solve. MSC therapy in Cancún, México is offered only as a possible biological adjunct — to the surrounding joint environment — and only when a Regeneris physician agrees it is appropriate after reviewing your imaging, surgical plan, and rehabilitation timeline.
A 2024–2025 systematic review and meta-analysis of five randomized controlled trials (221 patients, 109 receiving BMAC) found that BMAC augmentation of ACL reconstruction did not significantly improve early patient-reported outcomes (IKDC, Lysholm) at most time points, while MRI-related signals suggested possible improvements in graft recovery and complication rates were comparable to controls. The authors conclude potential biological benefit on imaging without clear early clinical superiority — i.e. an honest "promising but unproven" signal.
An exploratory clinical study applied a human umbilical-cord-blood-derived MSC plus hyaluronic acid mixture to the tendon–bone interface during ACL reconstruction. Over two years of follow-up the approach appeared safe with no treatment-related adverse events, but the authors did not find clinical evidence such as prevention of tunnel widening. The study is an honest example of how MSC adjuncts can be tolerated yet still fail to demonstrate a specific clinical benefit — a finding patients should know about.
A 2022 systematic review of stem cell therapy for tendon-graft ligamentization after ACL reconstruction concluded that stem cell approaches are a promising technique that can enhance biomechanical and histological properties of the graft in preclinical work, while emphasizing that human evidence is still maturing and that optimal delivery methods and timing are not yet established. The takeaway is consistent with the rest of the literature: a signal worth investigating, not a finished therapy.
Reading the evidence together: MSC-based adjuncts around ACL reconstruction are investigational, generally well tolerated under qualified supervision, and show a mixed but real signal — promising on some imaging endpoints, often modest on short-term patient-reported scores. That is exactly what we tell patients in Cancún, México before they decide.
There is no "yes for everyone" answer. The point of the free medical evaluation in Cancún, México is to honestly tell you whether MSC therapy is worth considering as an adjunct in your specific case — and to say no when it is not.
Every evaluation, infusion, and follow-up in Cancún, México is supervised by a licensed Mexican physician — including coordination with your treating orthopedic surgeon when appropriate. MSC therapy is never sold as an off-the-shelf product.
Our clinic is located at Av. Tulúm SM 11 MZ 1 Lote 1 Local 207, San Francisco, 77504 Cancún, Quintana Roo, México. International patients regularly fly into Cancún International Airport (CUN), and we coordinate scheduling around recovery timelines and travel logistics.
After the evaluation, you receive a written quote that reflects your individualized plan: which cell source, how many applications, follow-up cadence, and travel logistics for Cancún, México. Regeneris does not publish or quote standardized prices online.
This is deliberately a slower path than a typical retail medical website. ACL recovery is a months-long process; honest patient selection and honest expectations protect outcomes more than any single injection ever could.
If a clinic tells you something stronger than this, ask to see the specific peer-reviewed source — and ask whether it is in patients like you. That is exactly the conversation we expect to have with you in Cancún, México.
It means MSC therapy is offered, when appropriate, as an investigational biological adjunct to the orthopedic plan you already have — surgical reconstruction, physical therapy, and supervised return-to-sport. The intent is to modulate the post-injury or post-reconstruction inflammatory environment of the joint, consistent with how mesenchymal stem cells are now understood to work (paracrine signaling, not ligament re-growth). Recovery support is never a substitute for surgery or rehabilitation, and in our Cancún, México clinic it is only considered when a physician — and ideally your treating surgeon — agrees it is appropriate for your case.
Timing is individualized and decided with your orthopedic surgeon. In published randomized work, intra-articular MSC adjuncts have been studied after ACL reconstruction, often delivered as a single intra-articular injection in the post-operative period. In other studies, MSC-containing mixtures have been applied to the tendon–bone interface at the time of surgery. Both timings are investigational, and the best window for an individual patient depends on the surgical plan, graft type, comorbidities, and rehabilitation timeline — which is exactly what is discussed during the medical evaluation at Regeneris in Cancún, México.
There is no responsible way to promise that, and the evidence does not support that claim. Return-to-sport timing is determined by your orthopedic and rehabilitation team using objective criteria — strength symmetry, hop testing, neuromuscular control, and psychological readiness — not by a regenerative protocol. Some randomized adjunct studies after ACL reconstruction have reported imaging or joint-structural signals, but short-term patient-reported outcomes often look similar to standard care. We tell patients honestly in Cancún, México: MSC therapy is being investigated as a recovery-support adjunct, not as a shortcut.
In published adjunct studies after ACL reconstruction, intra-articular MSC and bone marrow aspirate concentrate (BMAC) approaches have generally been reported as safe and well tolerated under qualified supervision, with complication rates comparable to standard care. As a general rule, elective MSC therapy is deferred in active or recently treated malignancy, uncontrolled immunosuppression, active uncontrolled infection, and pregnancy or breastfeeding. Disclose every medication, supplement, and diagnosis at evaluation so our physicians in Cancún, México can screen you correctly and coordinate with your treating surgeon when relevant.
Because Regeneris Therapy operates as a COFEPRIS-regulated regenerative medicine clinic in Cancún, México — federally authorized, physician-led, and using cells expanded in certified laboratory conditions — under a regulatory framework that allows transparent access to MSC-based protocols that remain investigational in many jurisdictions. Cancún is internationally accessible via Cancún International Airport (CUN), and many of our patients combine evaluation, supervised infusion, and structured follow-up around a defined visit. Our role for ACL patients is to coordinate carefully with their orthopedic surgeon at home — never to compete with that care.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
How regenerative medicine is regulated and supervised in México, and what to ask any clinic before you commit.